Angiomyolipoma medical therapy: Difference between revisions
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Treatment and management of the [[Angiomyolipoma]] depends largely on size of the tumors, signs and symptoms, presence or absence of Life threatening hemorrhage, its association with the tuberous sclerosis and the presence of the comorbities. The mainstay of therapy is [[embolisation]]. | Treatment and management of the [[Angiomyolipoma]] depends largely on size of the tumors, signs and symptoms, presence or absence of Life threatening hemorrhage, its association with the tuberous sclerosis and the presence of the comorbities.<ref name="pmid3520013">{{cite journal| author=Oesterling JE, Fishman EK, Goldman SM, Marshall FF| title=The management of renal angiomyolipoma. | journal=J Urol | year= 1986 | volume= 135 | issue= 6 | pages= 1121-4 | pmid=3520013 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3520013 }}</ref> The mainstay of therapy is [[embolisation]]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
Revision as of 06:21, 1 August 2018
|
Angiomyolipoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiomyolipoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Angiomyolipoma medical therapy |
|
Risk calculators and risk factors for Angiomyolipoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
Treatment and management of the Angiomyolipoma depends largely on size of the tumors, signs and symptoms, presence or absence of Life threatening hemorrhage, its association with the tuberous sclerosis and the presence of the comorbities.[1] The mainstay of therapy is embolisation.
Medical Therapy
There is no medical treatment for angiomyolipoma. The mainstay of therapy is embolisation. Angiomyolipomas found incidentally usually require no therapy. Patients with loss of renal function should be monitored for:
- Hypertension
- Adverse effects of nephrotoxic drugs such as:
- NSAIDS
- IV contrast agents
References
- ↑ Oesterling JE, Fishman EK, Goldman SM, Marshall FF (1986). "The management of renal angiomyolipoma". J Urol. 135 (6): 1121–4. PMID 3520013.